ArticleMaterials today. Bio2025
Size-optimized ceria nanoparticles attenuate intervertebral disc degeneration by rescuing nucleus pulposus cell senescence via reducing oxidative stress and stimulating PI3K/AKT pathway.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Antioxidant Nanotherapies for Intervertebral Disk Degeneration: Progress and Prospects.Antioxidants (Basel, Switzerland) · 2026Review
- Edaravone-based precision antioxidative therapy alleviates intervertebral disc degeneration via the Nrf2/Aldh3a1 axis.Materials today. Bio · 2026Article
- From Environmental Exposure to Intervertebral Disc Degeneration: First Evidence of Pro-Degenerative Effects of Polyamide 6 Microplastics.Biomedicines · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intervertebral disc degeneration (IVDD), a condition characterized by nucleus pulposus (NP) cell senescence and extracellular matrix (ECM) degradation, is a major cause of degenerative spinal disorders. Current clinical management remains limited. In this study, we evaluate PEG600-coated ceria nanoparticles (CeNPs) of three sizes (1.2, 4, and 40 nm) for their potential to mitigate NP cell senescence and IVDD in rat model. Among them, the 4 nm-PEG600 CeNPs exhibited the highest therapeutic efficacy, which can be attributed to their low cytotoxicity and improved physiological stability within disc tissue. Mechanistically, CeNPs attenuated IVDD by countering ROS accumulation-induced NP senescence, as supported by assessments of ECM metabolism, senescence-associated secretory phenotype (SASP) expression, cellular senescence and proliferation, and mitochondrial function. Importantly, beyond their direct ROS-scavenging ability, the 4 nm PEG600-CeNPs suppressed cellular senescence through inhibition of AKT Ser473 phosphorylation in the PI3K-AKT pathway. These findings establish size-optimized CeNPs as a promising dual-targeting (antioxidant and anti-senescence) strategy for IVDD treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.